News

Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting Rocaltrol® City Tour·Hangzhou Station On July 15, 2023, the fourth stop of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting and Rocaltrol® City Tour” jointly organized by Pharmanovia & Hesena was successfully held at the Hangzhou Friendship Hotel. The original intention of the “City Tour” activity is to enhance the guiding role of the “Guidelines” for clinicians and promote the whole society to pay attention to the prevention and treatment of osteoporosis. We hope to use this activity to assist the Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association to jointly Promote the standardized diagnosis and treatment of osteoporosis, strengthen the linkage between hospitals and doctors at all levels, and improve the treatment and rehabilitation of osteoporotic fractures. The meeting agenda was set around the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022), and Professor Li Weixu, chairman of the Professional Committee of Osteoporosis and Bone Mineral Diseases of Zhejiang Medical Association, and the director-designate of Zhejiang Professional Committee of Osteoporosis were invited Committee member Professor Yang Lei and two professors presided over the meeting, and three speakers

Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting Rocaltrol® City Tour·Fuzhou Station On June 18, 2023, the third stop of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting and Rocaltrol® City Tour” co-sponsored by Pharmanovia & Hessina was successfully held in Fuzhou Grand Hotel. The establishment of Rocaltrol ® City Tour Project aims to enhance the guiding role of the “Guidelines” for clinicians through the form of city tours, and combine the latest clinical experience and methods in the standardized diagnosis and treatment of osteoporosis to help people at all levels The hospital improves the standardized diagnosis and treatment of osteoporosis and patient management, and hopes to take this opportunity to learn, exchange, and discuss together, so as to maximize its social responsibility of fighting osteoporosis, serving the clinic, and benefiting patients. Professor Yan Sunjie , Chairman of the conference, director of the Department of Endocrinology, the First Affiliated Hospital of Fujian Medical University Professor Yan first thanked everyone for participating in this meeting. Fuzhou is the third stop of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting and Rocaltrol® City Tour”, which illustrates the importance

Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting Rocaltrol® City Tour·Ji‘nan Station On June 13, 2023, the second stop of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting and Rocaltrol® City Tour” jointly organized by Pharmanovia & Hesena was held in Lanhai Yuhua, Jinan City, Shandong Province The Grand Hotel was successfully held. The original intention of the “City Tour” activity is to enhance the guiding role of the “Guide” to clinicians and promote the whole society to pay attention to the prevention and treatment of osteoporosis. We hope to use this activity to assist the Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association to jointly Promote the standardized diagnosis and treatment of osteoporosis, strengthen the linkage between hospitals and doctors at all levels, and improve the treatment and rehabilitation of osteoporotic fractures. The meeting agenda was set around the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022), and academic leaders were invited, members of the Osteoporosis and Bone Minerals Branch of the Chinese Medical Association, and directors of the Osteoporosis and Bone Minerals Branch of the Shandong Medical Association Committee member, chairman of the Osteoporosis

Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting  Rocaltrol® City Tour·Shanghai Station On June 7, 2023, the first event of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022) Interpretation Meeting and Rocaltrol® City Tour” jointly organized by Pharmanovia & Hesena was successfully held in Shanghai San Want Hotel. The original intention of the “City Tour” activity is to enhance the guiding role of the “Guide” to clinicians and promote the whole society to pay attention to the prevention and treatment of osteoporosis. We hope to use this activity to assist the Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association to jointly Promote the standardized diagnosis and treatment of osteoporosis, strengthen the linkage between hospitals and doctors at all levels, and improve the treatment and rehabilitation of osteoporotic fractures. The meeting agenda was set around the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022), and Zhang Zhenlin, the leader of the guideline writing group with profound academic attainments and the director of the Osteoporosis and Osteopathy Department of the Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, was invited The professor presided over the meeting,

Pharmanovia & Hesenna Lishui inspection report From May 23rd to 24th, 2023, the British pharmaceutical company Pharmanovia came to Lishui, known as the “Zhejiang Green Valley”, to conduct a two-day on-site inspection and meetings with Zhejiang Hesenna Medicine Co., Ltd. (Hesenna) . On the afternoon of May 23, Mr. Chen Wei, the representative of Pharmanovia’s controlling shareholder and the president of Deteng (Shanghai) Investment Consulting Co., Ltd., Mr. Dimitri Pimbert, the general manager of Pharmanovia’s Asia-Pacific region, Mr. Ian McAleer, the general manager of China, and Mr. Xin Huihao, the deputy general manager , Ms. Cui French, Chief Financial Officer, Mr. Huang Rui, Director of Market Access and Strategic Planning, Mr. Lu Xiaoyu, Director of Channels and Marketing, Mr. Gu Tianchao, Director of Supply Chain Management; Mr. Gu Lijun, Chairman of Zhejiang Hesenna Medicine, Ms. Li Shu, General Manager, Gong Gong, Director of BD Mr. Zhi met with Wu Shunze, Deputy Secretary of Lishui Municipal Party Committee and Mayor. The two parties conducted in-depth exchanges on the cooperation of the Luogai full product supply chain project under Pharmanovia and the Luogai full product China production subcontracting base project in Lishui Economic Development Zone. Liu Zhiwei, member of the party group

On April 13, 2023, Pharmanovia and Zhejiang Hesenna Medicine (hereinafter referred to as Hesenna) held a strategic cooperation conference and “Leaping Tiger” project (Rocaltrol) launch ceremony. Ian McAleer, General Manager of Pharmanovia China, and Mr. Gu, Chairman of Hesenna, signed the strategic cooperation agreement as representatives of both parties. This strategic cooperation release marks a more in-depth cooperation in more disease areas, including: endocrine, cardiovascular, oncology, neurology, etc; The launch of the ” Leapping Tiger ” project also marks the beginning of the joint promotion of Rocaltrol between the two sides, and Hesenna will upgrade the original marketing team to form a professional marketing team to be fully responsible for the academic promotion of Rocaltrol. After the release of the signing ceremony, the leaders of both sides made speeches to address: Mr.McAleer expressed the importance Pharmanovia attaches to the Chinese market and its determination to put down roots in China, and made it clear: “Pharmanovia and Hesenna share the same goal, and the Pharmanovia China team has rich experience in the field. Pharmanovia will have many new products to enter China, and we are looking forward to a bright future together!” Sean Xin, Deputy General Manager of Pharmanovia China, had